RxDoctor Payments Data

Robert Wang

Interventional Cardiology · Mountain Lakes, NJNPI 1043219876

Payments from drug & device makers

$9,953in general payments, 2019–2025

Across 482 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novartis$1K
  • AstraZeneca$636
  • Johnson & Johnson$614
  • Pfizer$593
  • Abiomed$585
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$9,80599%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,953 in reported general payments places this provider in the 50th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$520,411
Medicare patients
2,186
Services billed
7,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban716$795,656
XareltoRivaroxaban290$314,532
EntrestoSacubitril/Valsartan157$190,567
FarxigaDapagliflozin Propanediol78$92,951
MultaqDronedarone Hcl58$80,228
JardianceEmpagliflozin53$63,906
Metoprolol Succinate1,533$22,000
VascepaIcosapent Ethyl35$16,809
Repatha SureclickEvolocumab19$16,236
BrilintaTicagrelor18$15,732
Atorvastatin Calcium1,481$14,323
CrestorRosuvastatin Calcium13$9,616
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid89$8,746
Losartan Potassium782$7,737
Midodrine Hcl65$7,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$593$795,656716 claims
Johnson & JohnsonXarelto$614$314,532290 claims
NovartisEntresto$1,057$190,567157 claims
AstraZenecaFarxiga, Brilinta, Crestor$636$118,299109 claims
Sanofi-aventis U.S. LLCMultaq$489$80,22858 claims
Boehringer IngelheimJardiance$1,134$63,90653 claims
Kowa Pharmaceuticals America, Inc.Bystolic$134$6,59614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Mountain Lakes

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →